Poor set of number.
Nothing to be enthused about.
Revenues are showing no signs of bottoming out yet.
Though a bit of relief is even after bad numbers stock isn’t expensive based on TTM earnings.
So it’s possible we might not see much damage coz of numbers. Rest will know tomorrow how the market will react to the numbers posted today.
Hi, Prolife has 20crore plus as cash and cash equivalents as on 31/3/2024. A year ago it had onlye 1 crore plus as cash and cash equivalent.
This money would be used to expand and upgrade the capacities it seems. Promotor group is well respected by peers around Panoli Industrial Estate. They expecting that the upcoming results would reflect growth. Any update about the company, pls share
Hope balaji show good growth going forward
Not invested in that but looks like multibagger if mgt is able to execute its plan .
After disappointing quarters Jagsonpal Pharmaceuticals Limited posted is back on growth path. The company has reported quarterly revenue of Rs. 61.4 crores and operational EBITDA of Rs. 10.2 crores for the Q1FY25, which are higher both on QoQ and YoY basis. Net profit is Rs. 5.3 crores due to exceptional expanse of Rs. 3.3 crores incurred on acquisition of Yash Pharma.
Some interesting key points from the press release:
From the TTM financials, the company seems to be fairly valued, however, if the aggressive growth guidance of the management are met, the stock is available at discount to the peers. Capabilities of CEO Manish Gupta in running the show and clinching acquisition at good prices, who is also holding good amount of stake in the company is another optionality.
Disclaimer: Invested and biased
AIA Engineering
CMP ₹4471
Buyback price ₹5000
Record date 20 August
Thank you @Rajesh_Singh Sir for sharing your knowledge and insights with us. Sir, have you looked into Nirman Agri Genetics? Management is very ambitious and they are looking at 100% CAGR. There’s a lot of buzz regarding it amongst SME investors as well.
I don’t think the results are that great.
The operating costs of the company seem out of control. The expense to operating revenue ratio has surged to 1.32 ( 1.28 in Q1-24). The effect is not visible due to high other income on sale of land (2059 lakhs) which is exceptional in nature.
Ignoring the impact of exceptional other income, the Loss stands at 2232 lakhs ( 1141 lakhs in Q1-24)
That is widening of 95% approx.
The revenue of Foundry business has taken a hit of 18% yoy. No particular reason provided by the management for this variation.
Order book of 33,930 lakhs is on hold from customers end. No visibility of materialisation of the same.
Ofcourse the impact of finance cost savings on loan is will be visible from the next quarter.
Inviting everyone’s views on this.
Thanks for kind words @Amit_Paul. Yup did lot of churning post budget, reduced Kalyan on budget day, increased allocation in Samhi Hotels. Exited Sanghvi, Swelect, PVR, Piccadily, Betting on GE Shipping.
7% loss on Portfolio during this carnage. Rebalancing in progress, shunting non performers. Tough time ahead. Keeping only stocks where growth is visible or valuations are reasonable.
Yen carry trade is big, markets will be sideways for some time until turbulence is fully discounted.
